Experimental drug BGB-23339 tested for safety in 92 healthy people
NCT ID NCT05093270
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested the safety and tolerability of an experimental drug called BGB-23339 in 92 healthy adults. Participants received either the drug or a placebo as an oral tablet. The main goal was to see how the body handles the drug and whether it causes any side effects. Because this is a first-in-human study, it does not aim to treat any specific disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BGB-23339 (an experimental oral drug)
- What could go wrong
- This is a very early, first-in-human study in healthy people, so it cannot show whether the drug works for any disease. The results only tell us about safety and how the body processes the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOT DETERMINED are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network
Melbourne, Victoria, VIC 3004, Australia
-
Q PHARM
Herston, Queensland, QLD 4006, Australia
-
The Affiliated Hospital of Qingdao University Branch West Coast
Qingdao, Shandong, 266555, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.